Passage BIO, Inc. has provided an update on its clinical trial for REM-422, a novel treatment aimed at patients with adenoid cystic carcinoma (ACC). The recent press release highlights promising Phase 1 data, showcasing the drug's potential efficacy and safety profile. This announcement is significant as it underscores Passage BIO's ongoing commitment to developing innovative therapies in the competitive biological products sector.
Founded in Delaware, Passage BIO, Inc. operates in the biological products industry, specifically focusing on products without diagnostic substances. The company trades under the ticker PASG on the Nasdaq exchange. Recent filings indicate that Passage BIO is classified as a smaller reporting company.
The filing, dated November 19, 2026, includes Regulation FD disclosure and financial statements. It references a press release from Remix Therapeutics, Inc., which announced updated Phase 1 data for its own product, REM-422, during the 2026 EORTC-NCI-AACR Symposium. This highlights the competitive landscape in which Passage BIO operates, as it continues to develop its own therapies.
The updated data from the Phase 1 trial of REM-422 indicates a 57% overall response rate in biomarker-positive patients. This finding is particularly noteworthy given the lack of FDA-approved therapies for ACC, emphasizing the urgent need for effective treatments in this area. The trial has shown durable clinical activity, with some patients remaining on treatment for up to two years.
As Passage BIO moves forward, the results from this trial may influence future clinical development strategies and partnerships within the industry. The company’s focus on addressing unmet medical needs in cancer treatment positions it well among its peers.
Looking ahead, the filing does not specify the next steps for Passage BIO regarding further clinical trials or regulatory submissions. However, the promising data may lead to additional announcements as the company continues to navigate the complexities of drug development in the competitive biological products market.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










